American Doctor's Popular Posts

Showing posts with label new medical breakthroughs. Show all posts
Showing posts with label new medical breakthroughs. Show all posts

Wednesday, February 2, 2011

Communication Pathways Within Proteins May Yield New Drug Targets To Stop Superbugs



Communication Pathways Within Proteins May Yield New Drug Targets To Stop Superbugs

A School of Science at Indiana University-Purdue University Indianapolis biophysicist has developed a new method to identify communication pathways connecting distant regions within proteins. 

With this tool, Andrew J. Rader, Ph.D., assistant professor of physics, has identified a mechanism for cooperative behavior within an entire molecule, a finding that suggests that in the future it may be possible to design drugs that target anywhere along the length of a molecule's communication pathway rather than only in a single location as they do today. The discovery holds promise for increasing the likelihood of therapeutic success. 

The study, "Correlating Allostery with Rigidity" is published in the current issue ofMolecular BioSystems, a journal of the Royal Society of Chemistry. 

Microorganisms frequently contain enzymes, protein molecules that carry out most of the important functions of cells, not present in human cells. Blocking these enzymes can stop or kill a harmful invader. 

Drugs are often developed to block or restrict the function of such enzymes, thereby treating the underlying infectious disease they convey. These drugs often target specific chemical sites on bacterial or viral enzymes, and alter the enzymes so they no longer function. Unfortunately, microorganisms can evolve enzymes that are impervious to these drugs, resulting in drug resistant organisms. 

"With the growth of drug resistant organisms, it is increasingly important that we gain a better understanding of what makes enzymes within cellular proteins do what they do, so that we can develop alternative approaches to targeting these proteins, shutting down enzymes and killing these superbugs," said Rader, first author of the study. 

He has found that the "poking" of one spot on the rigid pathway connecting regions within proteins produces communication along the entire pathway, indicating that drugs could be targeted to multiple locations on the pathways that had not developed drug resistance and could travel to where needed. His new method identified more than twice as many communication pathways as previous studies. 

To use the analogy of a railroad track, dislocating a single rail, anywhere on the track, effects the entire track as trains cannot travel from one end to the other due to the rail that is out of alignment. Returning the rail to its proper location makes the entire track function normally. In the case of the rigid pathways within proteins, affecting a single chemical locus on the pathway affects the entire pathway. 

"We now see in these rigid pathways that we can effect something at a distance. This holds great potential for drug targeting. We can do something at one site on the pathway, where drug resistance is not an issue, and it will affect another, perhaps turning an enzyme off and eliminating drug resistance. It's too early to say whether we can successfully counter tuberculosis, Methicillin-resistant Staphylococcus aureus [MRSA] and others of the growing number of multidrug resistant organisms this way, but it's a promising approach well worth further exploration," said Rader. 

Notes: 

This study by Rader, co-authored by graduate student Stephen M. Brown, was funded by the Department of Physics, School of Science at IUPUI. 

Tuesday, January 25, 2011

Cleveland Clinic predicts top medical breakthrough of 2011


Cleveland Clinic predicts top medical breakthrough of 2011  


This week, at Cleveland Clinic's top 10 medical breakthroughs of 2011 have been predicted, with the new brain imaging compound AV-45--which is poised to help early detection of Alzheimer's--taking the top spot.


Alzheimer's gets its name from German psychiatrist Alois Alzheimer, who began lecturing in the early 1900s about the plaques and tangles he'd found in the post-mortem brain tissue of a 51-year-old patient.

To this day, diagnosing the disease while a patient is still alive is tricky, and there is still no cure. But there have been several breakthroughs in understanding how to identify the disease; elevated levels of the telltale protein tau, for instance, can appear decades before outward signs do.
After injecting the radioactive molecular imaging compound into a patient, AV-45 crosses the blood-brain barrier and binds to the beta-amyloid plaques that are also associated with Alzheimer's. PET imaging then enables physicians to see any dyed amyloid plaques and make a diagnosis.

Cleveland Clinic expects this new technique, invented by researchers at Avid Radiopharmaceuticals in Philadelphia, to earn FDA approval in 2011. The judges write:
It's thought that AV-45 can be used as a biomarker not only for diagnosing AD, but also for monitoring disease progress and drug efficacy. Once this novel compound receives its expected FDA approval in 2011, this dream could become a reality, paving the way for better ways to distinguish AD from Parkinson's disease and other types of dementia; using it as an effective method of tracking disease progression from mild cognitive impairment to late AD; and utilizing it as a key diagnostic in the development and testing of the more than 150 AD drugs presently in the pipeline.

Whether AV-45 will play the largest role in the diagnosis of Alzheimer's remains to be seen, but it represents a major advance in earlier detection of the disease